0000899243-22-021008.txt : 20220603 0000899243-22-021008.hdr.sgml : 20220603 20220603170658 ACCESSION NUMBER: 0000899243-22-021008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220601 FILED AS OF DATE: 20220603 DATE AS OF CHANGE: 20220603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith-Whitley Kim CENTRAL INDEX KEY: 0001860297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 22995617 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001860297 Smith-Whitley Kim C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-06-01 4 M 0 6040 A 6040 D Common Stock 2022-06-01 4 F 0 1660 24.02 D 4380 D Restricted Stock Units 2022-06-01 4 M 0 6040 0.00 D Common Stock 6040 18120 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,040 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vested with respect to 25% of the underlying shares on June 1, 2022 and will vest in six equal semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Officer Title: EVP, Head of Research & Development /s/ Miguel Carrillo, Attorney-in-Fact 2022-06-03